Clinical trial · Interventional
Study of the Effect of GM-CSF on Macrophages in Ependymoma
Pilot Study of the Effect of GM-CSF on Macrophages in Incompletely Resected or Recurrent Ependymoma
NCT04408092CI-TRIAL-00075034completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ependymoma | Ependymoma | ONTOLOGY_EXACT | 0.90 |
| Ependymoma, Recurrent Childhood | Childhood Ependymoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Granulocyte Macrophage Colony Stimulation Factor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- GM-CSF treatment at second-look surgery arm
- description
- Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
- interventionNames
- Drug: Granulocyte Macrophage Colony Stimulation Factor
- type
- EXPERIMENTAL
- label
- GM-CSF treatment at recurrence arm.
- description
- EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients. Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Months
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 12 months and \< 21 years at the time of study enrollment. * Patients must be one of the following: • Newly diagnosed with posterior fossa ependymoma with a subtotal resection at initial surgery. These patients will be eligible for stratum 1. * Be in first relapse of their posterior fossa ependymoma. These patients will be eligible for stratum 2. * Histologically confirmed diagnosis of intracranial ependymoma . * Pre or post-operative MR imaging of the brain demonstrates no evidence of non-contiguous spread beyond the primary site * Pre or post-operative MR imaging of the spine demonstrates no evidence of non-contiguous spread beyond the primary site * Pre-operative CSF cytology obtained from the lumbar CSF space demonstrated no evidence of non-contiguous spread beyond the primary site. • The requirement for lumbar CSF examination may be waived if deemed to be medically contraindicated. * Patients must meet one of the following performance scores. • ECOG performance status scores of 0, 1, or 2. * Karnofsky score of ≥ 50 for patients \> 16 years of age or Lansky score of ≥ 50 for patients ≤ 16 years of age * Organ Function Requirements: Adequate renal function defined as: * Creatinine clearance or radioisotope GFR ³ 70ml/min/1.73 m2 or * A serum creatinine based on age/gender as follows: Age Maximum Serum Creatinine (mg/dL) Male Female 1 month to \< 6 months 0.4 0.4 6 months to \< 1 year 0.5 0.5 1 to \< 2 years 0.6 0.6 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1 1 10 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4 ≥ 16 years 1.7 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC. * Adequate liver function defined as: * Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age, and * SGOT (AST) or SGPT (ALT) \< 3 x upper limit of normal (ULN) for age. * Patients with Gilbert syndrome or hemolytic anemia are eligible if total bilirubin is \< 3 x upper limit of normal (ULN) for age. * Adequate Bone Marrow Function defined as: * Peripheral absolute neutrophil count (ANC) \>= 1,000/uL * Platelet count \>= 100,000/uL (transfusion independent). Exclusion Criteria: * Patients with a diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, supratentorial ependymoma, or mixed glioma are NOT eligible. * Patients with evidence of metastatic disease by MRI or CSF cytology are NOT eligible
References
Publications (0)
Data not yet available
No reference posted for this study.